APR Applied Pharma Research s.a. (wholly owned by Relief Therapeutics Holding AG, SIX: RLF.SW), is a B2B Swiss-based international biopharma focused on development and global commercialization of innovative, patent protected products designed to address unmet needs.
Products, services, technology
ACT: Products
- CNS/Pain/Mìgraine: Diclofenac Potassium (various forms and dosage forms)
- CINV/PONV: Ondansetron ODF
- Rare Metabolics: RLF-OD032 (PKU), Golike (PKU, TYR), Olpruva (UCD)
- Rare Dermatology: RLF-TD011 (EB)
Tech Platforms
- Physiomimic Platform
- TEHCLO Platform
Cooperation possibilities
B2B/Licensing business:
a) Licensing-in activities of de-risked Tx assets
b) Licensing-out products and tech platforms on a global basis.
Contract services to 3rd parties: concept, design, formulation, re-formulation, IP liaison, R&D & QC analytical services.
- http://www.apr.ch
- Send an email
- Stefano Balestrini
